Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
KOOL's Cash to Debt is ranked higher than
89% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. KOOL: No Debt )
KOOL' s 10-Year Cash to Debt Range
Min: 0.87   Max: No Debt
Current: No Debt

Equity to Asset 0.77
KOOL's Equity to Asset is ranked higher than
82% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. KOOL: 0.77 )
KOOL' s 10-Year Equity to Asset Range
Min: 0.45   Max: 0.91
Current: 0.77

0.45
0.91
Interest Coverage No Debt
KOOL's Interest Coverage is ranked higher than
75% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 241.11 vs. KOOL: No Debt )
KOOL' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -0.98
M-Score: 79.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -62.68
KOOL's Operating margin (%) is ranked higher than
54% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. KOOL: -62.68 )
KOOL' s 10-Year Operating margin (%) Range
Min: -218.18   Max: -9.09
Current: -62.68

-218.18
-9.09
Net-margin (%) -60.18
KOOL's Net-margin (%) is ranked higher than
54% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. KOOL: -60.18 )
KOOL' s 10-Year Net-margin (%) Range
Min: -218.18   Max: -3.03
Current: -60.18

-218.18
-3.03
ROE (%) -30.80
KOOL's ROE (%) is ranked higher than
56% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. KOOL: -30.80 )
KOOL' s 10-Year ROE (%) Range
Min: -141.18   Max: -13.56
Current: -30.8

-141.18
-13.56
ROA (%) -24.07
KOOL's ROA (%) is ranked higher than
57% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. KOOL: -24.07 )
KOOL' s 10-Year ROA (%) Range
Min: -106.67   Max: -10.6
Current: -24.07

-106.67
-10.6
ROC (Joel Greenblatt) (%) -144.53
KOOL's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. KOOL: -144.53 )
KOOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -234.15   Max: -36.5
Current: -144.53

-234.15
-36.5
Revenue Growth (%) -25.20
KOOL's Revenue Growth (%) is ranked higher than
50% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. KOOL: -25.20 )
KOOL' s 10-Year Revenue Growth (%) Range
Min: -25.2   Max: 20.4
Current: -25.2

-25.2
20.4
EBITDA Growth (%) 27.30
KOOL's EBITDA Growth (%) is ranked higher than
93% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. KOOL: 27.30 )
KOOL' s 10-Year EBITDA Growth (%) Range
Min: -38.9   Max: 271.4
Current: 27.3

-38.9
271.4
EPS Growth (%) 28.40
KOOL's EPS Growth (%) is ranked higher than
92% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. KOOL: 28.40 )
KOOL' s 10-Year EPS Growth (%) Range
Min: -36.4   Max: 278
Current: 28.4

-36.4
278
» KOOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

KOOL Guru Trades in Q2 2013

Jim Simons 191,000 sh (+2.85%)
» More
Q3 2013

KOOL Guru Trades in Q3 2013

Jim Simons 222,000 sh (+16.23%)
» More
Q4 2013

KOOL Guru Trades in Q4 2013

Jim Simons 187,700 sh (-15.45%)
» More
Q1 2014

KOOL Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KOOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2011-09-30 Sold Out 0.0001%$1.2 - $2.13 $ 1.11-36%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.98
KOOL's P/B is ranked higher than
95% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. KOOL: 0.98 )
KOOL' s 10-Year P/B Range
Min: 0.16   Max: 5.18
Current: 0.98

0.16
5.18
P/S 2.09
KOOL's P/S is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. KOOL: 2.09 )
KOOL' s 10-Year P/S Range
Min: 0.18   Max: 6.52
Current: 2.09

0.18
6.52
EV-to-EBIT -3.39
KOOL's EV-to-EBIT is ranked higher than
55% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. KOOL: -3.39 )
KOOL' s 10-Year EV-to-EBIT Range
Min: -17.3   Max: 1.7
Current: -3.39

-17.3
1.7
Current Ratio 3.78
KOOL's Current Ratio is ranked higher than
79% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. KOOL: 3.78 )
KOOL' s 10-Year Current Ratio Range
Min: 1.52   Max: 16.85
Current: 3.78

1.52
16.85
Quick Ratio 2.74
KOOL's Quick Ratio is ranked higher than
77% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. KOOL: 2.74 )
KOOL' s 10-Year Quick Ratio Range
Min: 0.86   Max: 15.88
Current: 2.74

0.86
15.88

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.88
KOOL's Price/Net Current Asset Value is ranked higher than
82% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. KOOL: 13.88 )
KOOL' s 10-Year Price/Net Current Asset Value Range
Min: 0.3   Max: 71.88
Current: 13.88

0.3
71.88
Price/Tangible Book 4.27
KOOL's Price/Tangible Book is ranked higher than
77% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. KOOL: 4.27 )
KOOL' s 10-Year Price/Tangible Book Range
Min: 0.23   Max: 36.11
Current: 4.27

0.23
36.11
Price/Median PS Value 1.35
KOOL's Price/Median PS Value is ranked higher than
65% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. KOOL: 1.35 )
KOOL' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 11.69
Current: 1.35

0.19
11.69
Earnings Yield (Greenblatt) -29.50
KOOL's Earnings Yield (Greenblatt) is ranked lower than
52% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. KOOL: -29.50 )
KOOL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 58   Max: 10492.9
Current: -29.5

58
10492.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:THRA.Germany
Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp, founded in 1986 in California. The Company is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. It serves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking markets. The Company offers SurgWerks, a therapeutic technology platform, in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also offers CellWerks, an indication-specific device/protocol program for select applications in umbilical cord blood banking, bone marrow transplantation, and regenmed bioprocess markets. The Company complies under a variety of Good practices concerning operation of clinical cell manufacturing, processing, testing, and storage facilities, as well as patient safety, quality laboratory documentation, and quality cell processing and handling. It supports production of personalized medicine prescriptions and large scale batch processes. The Company has the ability to support various device prototyping and validation, typically required in a combination product. Its clinical research organization is specialized, in-hospital and cell therapy CRO.
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
comment on KOOL Dec 01 2011 
comment on KOOL Aug 26 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Cesca Therapeutics Invited to Present at LD Micro Conference and the World Stem Cell Summit Nov 26 2014
Cesca Therapeutics Announces Filing of U.S. Pivotal IDE Application for No-Option Critical Limb... Nov 24 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 21 2014
CESCA THERAPEUTICS INC. Financials Nov 21 2014
Cesca Therapeutics Announces Filing of U.S. Pivotal IDE Application for No-Option Critical Limb... Nov 20 2014
10-Q for Cesca Therapeutics, Inc. Nov 18 2014
CESCA THERAPEUTICS REPORTS FIRST QUARTER FISCAL 2015 RESULTS Nov 14 2014
CESCA THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report Nov 14 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 13 2014
Cesca Therapeutics Reports First Quarter Fiscal 2015 Results Nov 13 2014
Cesca Therapeutics to Announce First Quarter Fiscal 2015 Results on November 13, 2014 Nov 12 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 03 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Oct 30 2014
Cesca Therapeutics Announces Change in Executive Leadership Oct 29 2014
Cesca Therapeutics Announces Agreement With New York Upstate Cord Blood Bank Oct 13 2014
Cesca Therapeutics to Present at Stem Cell Meeting on the Mesa Oct 06 2014
10-K for Cesca Therapeutics, Inc. Oct 01 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Sep 29 2014
Cesca Therapeutics Announces Approval of Its AXP(R) AutoXpress(R) System in Taiwan Sep 29 2014
Cesca Therapeutics Reports Fourth Quarter and Full Fiscal 2014 Results Sep 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK